Related Experiment Video
Updated: Jul 9, 2025
05:06
Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
Published on: November 10, 2023
1.0K
Dynamic immuno-nanomedicines in oncology
Hao Ling1, Qinyi Zhang2, Qiuhua Luo3
1Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
Summary
Dynamic immuno-nanomedicines (DINMs) leverage reactive oxygen species to enhance anti-tumor immunity, overcoming immunotherapy resistance. This review explores DINMs
Area of Science:
- Oncology
- Immunology
- Nanomedicine
Background:
- Immunotherapy advances cancer treatment by harnessing the immune system against tumors.
- Tumor cells frequently evade immune detection, leading to immunotherapy resistance and tolerance.
- Potentiating anti-tumor immunity in immunotherapy-resistant patients is a critical clinical challenge.
Purpose of the Study:
- To review the pivotal role of dynamic immuno-nanomedicines (DINMs) in cancer immunotherapy.
- To provide an overview of the clinical realities and preclinical development of emerging DINMs.
- To summarize strategies for synergizing anti-tumor immunity with DINMs and discuss future challenges and opportunities.
Main Methods:
- Literature review focusing on reactive oxygen species-based dynamic nanotherapeutics.
- Analysis of the immunomodulatory potential of dynamic nanotherapeutics.
- Synthesis of information on clinical applications, preclinical developments, and combination strategies involving DINMs.
Main Results:
- Dynamic nanotherapeutics, conceptualized as DINMs, demonstrate significant potential to enhance anti-tumor immune responses.
- DINMs can overcome common mechanisms of immune escape and improve immunotherapy efficacy.
- Emerging DINMs show promise in preclinical settings, with various combination strategies being explored.
Conclusions:
- DINMs represent a promising therapeutic strategy to enhance cancer immunotherapy by modulating the tumor immune microenvironment.
- Further research and clinical development are needed to fully realize the potential of DINMs in treating immunotherapy-resistant cancers.
- Synergistic combinations of DINMs with other immunologic agents offer opportunities to overcome treatment resistance and improve patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:27Cytotoxic T Cells-mediated Immune Response
923
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
923
01:30Cancer Vaccines
376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376